Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio

Annals of Pharmacotherapy

Volumn 52, Issue 7, 2018, Pages 632-638

  Kaneko, Masayuki ^a   Narukawa, Mamoru ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

antihyperglycemics; cardiology; clinical trials; drug safety; type 2 diabetes

Indexed keywords

EXENDIN 4; LIRAGLUTIDE; LIXISENATIDE; PLACEBO; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC PATIENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CODING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTED MEAN SURVIVAL TIME; SURVIVAL TIME; CARDIOVASCULAR DISEASE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EXENATIDE; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; PEPTIDES; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 85044027784     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028018757407     Document Type: Article

References (35)

1. US Department of Health and Human Services, Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf. Accessed December 31, 2017.
2. Garber AJ., Novel GLP-1 receptor agonists for diabetes. Expert Opin Investig Drugs. 2012;21:45-57. doi:10.1517/13543784.2012.638282.
3. Pfeffer MA, Claggett B, Diaz R, ; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247-2257. doi:10.1056/NEJMoa1509225.
4. Marso SP, Daniels GH, Brown-Frandsen K. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322. doi:10.1056/NEJMoa1603827.
5. Marso SP, Bain SC, Consoli A, ; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844. doi:10.1056/NEJMoa1607141.
6. Holman RR, Bethel MA, Mentz RJ, ; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-1239. doi:10.1056/NEJMoa1612917.
7. Gerstein HC, Colhoun HM, Dagenais GR. Design and baseline characteristics of participants in the researching cardiovascular events with a weekly INcretin in diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20:42-49. doi:10.1111/dom.13028.
8. Uno H, Claggett B, Tian L. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32:2380-2385. doi:10.1200/JCO.2014.55.2208.
9. Uno H, Wittes J, Fu H. Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies. Ann Intern Med. 2015;163:127-134. doi:10.7326/M14-1741.
10. Trinquart L, Jacot J, Conner SC, Porcher R., Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. J Clin Oncol. 2016;34:1813-1819. doi:10.1200/JCO.2015.64.2488.
11. Chappell R, Zhu X., Describing differences in survival curves. JAMA Oncol. 2016;2:906-907. doi:10.1001/jamaoncol.2016.0001.
12. Zucker DM., Restricted mean life with covariates: modification and extension of a useful survival analysis method. J Am Stat Assoc. 1998;93:702-709. doi:10.1080/01621459.1998.10473722.
13. Royston P, Parmar MK., The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30:2409-2421. doi:10.1002/sim.4274.
14. Zhao L, Tian L, Uno H. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study. Clin Trials. 2012;9:570-577. doi:10.1177/1740774512455464.
15. Royston P, Parmar MK., Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152. doi:10.1186/1471-2288-13-152.
16. Guyot P, Ades AE, Ouwens MJ, Welton NJ., Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi:10.1186/1471-2288-12-9.
17. Wan X, Peng L, Li Y., A review and comparison of methods for recreating individual patient data from published Kaplan-Meier survival curves for economic evaluations: a simulation study. PLoS One. 2015;10:e0121353. doi:10.1371/journal.pone.0121353.
18. R Foundation for Statistical Computing. R: a language and environment for statistical computing. https://www.R-project.org/. Accessed January 23, 2018.
19. White WB, Cannon CP, Heller SR. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-1335. doi:10.1056/NEJMoa1305889.
20. Scirica BM, Bhatt DL, Braunwald E. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326. doi:10.1056/NEJMoa1307684.
21. Green JB, Bethel MA, Armstrong PW. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-242. doi:10.1056/NEJMoa1501352.
22. US Department of Health and Human Services, Food and Drug Administration. Onglyza [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022350s014lbl.pdf. Accessed December 31, 2017.
23. US Department of Health and Human Services, Food and Drug Administration. Nesina [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s005lbl.pdf. Accessed December 31, 2017.
24. Zinman B, Wanner C, Lachin JM. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi:10.1056/NEJMoa1504720.
25. Neal B, Perkovic V, Mahaffey KW. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. doi:10.1056/NEJMoa1611925.
26. US Department of Health and Human Services, Food and Drug Administration. Jardiance [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204629s016lbl.pdf. Accessed December 31, 2017.
27. US Department of Health and Human Services, Food and Drug Administration. Invokana [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204042s026lbl.pdf Accessed December 31, 2017.
28. Son JW, Kim S., Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies. Diabetes Metab J. 2015;39:373-383. doi:10.4093/dmj.2015.39.5.373.
29. Schernthaner G, Cahn A, Raz I., Is the use of DPP-4 inhibitors associated with an increased risk for heart failure? Lessons from EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes Care. 2016;39(suppl 2):S210-S218. doi:10.2337/dcS15-3009.
30. Fisher M., The CANVAS trial programme raises more questions than answers. Pract Diab. 2017;34:232-233. doi:10.1002/pdi.2125.
31. Monami M, Zannoni S, Nreu B, Mannucci E., Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetol. 2017;54:411-413. doi:10.1007/s00592-016-0928-z.
32. Kaneko M, Narukawa M., Assessment of the risk of hospitalization for heart failure with dipeptidyl peptidase-4 inhibitors, saxagliptin, alogliptin, and sitagliptin in patients with type 2 diabetes, using an alternative measure to the hazard ratio. Ann Pharmacother. 2017;51:570-576. doi:10.1177/1060028017698496.
33. Marx N, Rosenstock J, Kahn SE. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res. 2015;12:164-174. doi:10.1177/1479164115570301.
34. US National Library of Medicine, Clinicaltrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). https://clinicaltrials.gov/ct2/show/NCT01730534. Accessed December 31, 2017.
35. US Department of Health and Human Services, Food and Drug Administration. Victoza [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf Accessed December 31, 2017.